Impact of Cyclooxygenase-2 and Prostaglandin-E2 Expression on Clinical Outcome After Pulmonary Metastasectomy

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2017 Apr 29

PMID 28449470

Citations 3

Authors

Christian Lang

Emilie Hrdliczka

Thomas Schweiger

Olaf Glueck

Gerrit Lewik

Stefan Schwarz

Alberto Benazzo

Gyorgy Lang

Walter Klepetko

Konrad Hoetzenecker

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary metastasectomy (PM) is a standard procedure in the treatment of stage IV colorectal cancer (CRC). In most centers the indication for PM is solely based on clinical factors without taking the tumor biology into account. This results in diverse outcomes ranging from long-term remission to early recurrence. Inflammation is considered a hallmark of cancer development and progression. On the other hand the accessibility of CRC cells to the immune system reflects the grade of tumor aggressiveness. We sought to investigate the impact of cyclooxygenase-2 (COX-2) and prostaglandin-E2 (PGE2) expression in pulmonary metastases on different outcome parameters following PM.

Methods: From 04/2009 to 11/2013 53 patients with complete PM for CRC were included in this single-center study. Tissue samples of resected pulmonary metastases and available corresponding primaries were collected and assessed by immunohistochemistry for COX-2 and PGE2 expression of the tumor tissue and the peritumoral stroma. Results were correlated with clinical outcome parameters.

Results: COX-2 and PGE2 were detected in nearly every pulmonary CRC metastasis. Staining intensities of pulmonary metastases correlated only weakly with intensities found in primary tumors. When dividing metastases in high expressing and low expressing tumors, a trend towards longer recurrence free survival and improved survival was found in tumors with strong COX-2 and PGE2 staining.

Conclusions: In conclusion, this pilot study shows that COX-2 and PGE2 are uniformly overexpressed in pulmonary metastases from CRC. High expression of COX-2 and PGE2 seems to reflect a beneficial tumor biology with late tumor recurrence and prolonged overall survival after PM.

Citing Articles

Redox-Responsive Dual Drug Delivery Nanosystem Suppresses Cancer Repopulation by Abrogating Doxorubicin-Promoted Cancer Stemness, Metastasis, and Drug Resistance.

Liu J, Chang B, Li Q, Xu L, Liu X, Wang G Adv Sci (Weinh). 2019; 6(7):1801987.

PMID: 31139556 PMC: 6446919. DOI: 10.1002/advs.201801987.

Mutational profile of colorectal cancer lung metastases and paired primary tumors by targeted next generation sequencing: implications on clinical outcome after surgery.

Schweiger T, Liebmann-Reindl S, Glueck O, Starlinger P, Laengle J, Birner P J Thorac Dis. 2019; 10(11):6147-6157.

PMID: 30622786 PMC: 6297399. DOI: 10.21037/jtd.2018.10.72.

Pulmonary metastasectomy for colorectal cancer: analysis of prognostic factors affecting survival.

Ampollini L, Gnetti L, Goldoni M, Viani L, Faedda E, Campanini N J Thorac Dis. 2017; 9(Suppl 12):S1282-S1290.

PMID: 29119016 PMC: 5653500. DOI: 10.21037/jtd.2017.07.100.

References

Schweiger T, Starkl V, Glueck O, Glogner C, Traxler D, Jedamzik J . Clinical impact of c-MET expression and mutational status in patients with colorectal cancer lung metastases. Eur J Cardiothorac Surg. 2015; 49(4):1103-11. DOI: 10.1093/ejcts/ezv323. View

Coussens L, Zitvogel L, Palucka A . Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science. 2013; 339(6117):286-91. PMC: 3591506. DOI: 10.1126/science.1232227. View

Wu A, Gu J, Ji J, Li Z, Xu G . Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol. 2003; 9(9):1990-4. PMC: 4656659. DOI: 10.3748/wjg.v9.i9.1990. View

Hwang M, Park J, Kim D, Chang H, Kim S, Choi H . Early intrapulmonary recurrence after pulmonary metastasectomy related to colorectal cancer. Ann Thorac Surg. 2010; 90(2):398-404. DOI: 10.1016/j.athoracsur.2010.04.058. View

Schweiger T, Kollmann D, Nikolowsky C, Traxler D, Guenova E, Lang G . Carbonic anhydrase IX is associated with early pulmonary spreading of primary colorectal carcinoma and tobacco smoking. Eur J Cardiothorac Surg. 2013; 46(1):92-9. DOI: 10.1093/ejcts/ezt542. View

Zelenay S, van der Veen A, Bottcher J, Snelgrove K, Rogers N, Acton S . Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell. 2015; 162(6):1257-70. PMC: 4597191. DOI: 10.1016/j.cell.2015.08.015. View

Rotolo N, De Monte L, Imperatori A, Dominioni L . Pulmonary resections of single metastases from colorectal cancer. Surg Oncol. 2007; 16 Suppl 1:S141-4. DOI: 10.1016/j.suronc.2007.10.007. View

Sano H, Kawahito Y, Wilder R, Hashiramoto A, Mukai S, Asai K . Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995; 55(17):3785-9. View

Schweiger T, Berghoff A, Glogner C, Glueck O, Rajky O, Traxler D . Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. Clin Exp Metastasis. 2016; 33(7):727-39. PMC: 5035322. DOI: 10.1007/s10585-016-9813-y. View

10.

Lipsyc M, Yaeger R . Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol. 2015; 6(6):645-9. PMC: 4671855. DOI: 10.3978/j.issn.2078-6891.2015.045. View

11.

Wang D, DuBois R . Eicosanoids and cancer. Nat Rev Cancer. 2010; 10(3):181-93. PMC: 2898136. DOI: 10.1038/nrc2809. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

Kawamori T, Uchiya N, Sugimura T, Wakabayashi K . Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis. 2003; 24(5):985-90. DOI: 10.1093/carcin/bgg033. View

14.

Schweiger T, Hegedus B, Nikolowsky C, Hegedus Z, Szirtes I, Mair R . EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. Ann Surg Oncol. 2013; 21(3):946-54. DOI: 10.1245/s10434-013-3386-7. View

15.

Habib A, Creminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J . Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J Biol Chem. 1993; 268(31):23448-54. View

16.

Kargman S, ONeill G, Vickers P, Evans J, Mancini J, Jothy S . Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 1995; 55(12):2556-9. View

17.

Meric J, Rottey S, Olaussen K, Soria J, Khayat D, Rixe O . Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol. 2006; 59(1):51-64. DOI: 10.1016/j.critrevonc.2006.01.003. View

18.

Losi L, Bouzourene H, Benhattar J . Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. Oncol Rep. 2007; 17(5):1095-9. View

19.

Page D, Postow M, Callahan M, Allison J, Wolchok J . Immune modulation in cancer with antibodies. Annu Rev Med. 2013; 65:185-202. DOI: 10.1146/annurev-med-092012-112807. View

20.

Peng L, Zhou Y, Wang Y, Mou H, Zhao Q . Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature. PLoS One. 2013; 8(3):e58891. PMC: 3604072. DOI: 10.1371/journal.pone.0058891. View